Blog

Appendix 4D and Half Yearly Accounts 0

Appendix 4D and Half Yearly Accounts

[ad_1] Bausch Health (excl. B+L) R&D Update Amiselimod (S1P modulator): once-daily oral treatment of mild to moderate ulcerative colitis Phase 2 study completed enrollment...